Authors: Mindie H. Nguyen, Grace Wong, Edward Gane, Jia-Horng Kao, Geoffrey Dusheiko
Published: 2020-02-25
DOI: 10.1128/cmr.00046-19
Source: Full article
Currently, despite the use of a preventive vaccine for several decades as well as the use of effective and well-tolerated viral suppressive medications since 1998, approximately 250 million people remain infected with the virus that causes hepatitis B worldwide. Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the leading causes of liver cancer and overall mortality globally, surpassing malaria and tuberculosis. Linkage to care is estimated to be very poor both in developing countries and in high-income countries, such as the United States, countries in Western Europe, and Japan.